Relationship of Anti-vimentin antibodies to anti-endothelial antibodies

• Authors: Karin Malickova , Ivana Janatkova , Petra Sandova , Terezie Fucikova
• Languages of publication: EN

Abstracts

EN

The intermediate filament protein vimentin is a potential target antigen for autoantibodies in some infectious and autoimmune diseases. Because endothelial cells contain an extensive interconnecting cytoplasmic network of vimentin, we examined the relationship between anti-vimentin and anti-endothelial cell antibodies (AECAs). We measured the level of anti-vimentin antibodies in patients with systemic autoimmune diseases (n=42), healthy blood donors (n=58), and patients with acute inflammation and showing anti-vimentin immunofluorescence (n=50). AECAs were detected by indirect immunofluorescence in human umbilical vein endothelial cells. Anti-vimentin antibodies were detected by indirect immunofluorescence in HEp-2 cells, and levels of anti-vimentin antibodies were measured using an enzyme-linked immunosorbent assay. We did not find significant differences in anti-vimentin levels between AECA-positive and-negative samples for any of the groups; however, serum anti-vimentin antibody levels were significantly higher in patients with acute non-autoimmune inflammatory diseases than in patients with systemic autoimmune diseases or healthy controls. There were no differences between the levels of anti-vimentin antibodies between patients with systemic autoimmune diseases and healthy individuals. The anti-vimentin antibodies levels also did not correlate with the AECA positivity.

Keywords

EN

Endothelial cells; vimentin; vimentin; human umbilical vein endothelial cells (HUVEC); vascular disease

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2006
• Volume: 1
• Issue: 3
• Pages: 228-236

Dates

published

1 - 9 - 2006

online

1 - 9 - 2006

Contributors

author

Karin Malickova

author

Ivana Janatkova

author

Petra Sandova

• Institute of Clinical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and First Faculty of Medicine, Charles University, 120 00, Prague, Czech Republic

author

Terezie Fucikova

References

• [1] A. Kollmeier, M. Kreditor, J. George, Y. Levy and Y. Shoenfeld: “Functional properties of antiendothelial cell antibodies”, Clin. Rev. Allergy Immunol., Vol. 16, (1998), pp. 297–302. [Crossref]
• [2] Z.A. Yazici, M. Behrendt, D. Cooper, M. Goodfield, L. Partridge and N.J. Lindsey: “The identification of endothelial cell autoantigens”, J. Autoimmun., Vol. 15, (2000), pp. 41–49. http://dx.doi.org/10.1006/jaut.2000.0391[Crossref]
• [3] A.M. Azimzadeh, S. Pfeiffer, G.S. Wu, C. Schroder, H. Zhou, G.L. Zorn and M. Kehr: “Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates”, Am. J. Transplant., Vol. 5, (2005), pp. 2349–2359. http://dx.doi.org/10.1111/j.1600-6143.2005.01022.x[Crossref]
• [4] S. Jurcevic, M.E. Ainsworth, A. Pomerance and J.D. Smith: “Anti-vimentin antibodies are an independent predictor of transplant-associated coronary artery disease following cardiac transplantation”, Transplantation, Vol. 71, (2001), pp. 7–15
• [5] M.L. Rose: “Anti-vimentin antibodies are an independent predictor of transplantassociated coronary artery disease following cardiac transplantation”, Ital. Heart J., Vol. 2, (2001), pp. 23S–25S
• [6] L. Bretherton, B.H. Toh and I. Jack: “IgM autoantibody to intermediate filaments in Mycoplasma pneumoniae infections”, Clin. Immunol. Immunopathol., Vol. 18, (1982), pp. 425–430. http://dx.doi.org/10.1016/0090-1229(81)90135-5[Crossref]
• [7] Y. Yang, J. Fujita, S. Bandoh, Y. Ohtsuki, I. Yamadori and T. Yoshinouchi: “Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia”, Clin. Exp. Immunol., Vol. 128, (2002), pp. 169–173 http://dx.doi.org/10.1046/j.1365-2249.2002.01811.x[Crossref]
• [8] M.W. Bohme, D.A. Evans and M.A. Miles: “Occurrence of autoantibodies to intermediate filament proteins in human visceral leishmaniasis and their induction by experimental polyclonal B-cell activation”, Immunology, Vol. 59, (2000), pp. 583–588.
• [9] A.M. Gown and A.M. Vogel: “Monoclonal antibodies to human intermediate filament proteins. III. Analysis of tumors”, Am. J. Clin. Pathol., Vol. 84, (1985), pp. 413–424.
• [10] U.K. Laemmli: “Cleavage of structural proteins during the assembly of the head of bacteriophage T4”, Nature, Vol. 27, (1970), pp. 6805–6807
• [11] A. Alcover, J. Molano and J. Renart: “Antibodies to vimentin intermediate filaments in sera from patients with systemic lupus erythematosus”, Arthritis Rheum., Vol. 27, (1984), pp. 922–928. [Crossref]
• [12] P.K. Kataaha, S.M. Mortazavi-Milani and G. Russell: “Anti-intermediate filament antibodies, antikeratin antibody, and antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis”, Ann. Rheum. Dis., Vol. 44, (1985), pp. 446–449. [Crossref]
• [13] P. Kurki, T. Helve and I. Virtanen: “Antibodies to cytoplasmic intermediate filaments in rheumatic diseases”, J. Rheumatol., Vol. 10, (1983), pp. 558–562.
• [14] W.J. Mayet, A.G. Press and E. Hermann: “Antibodies to cytoskeletal proteins in patients with Crohn’s disease”, Eur. J. Clin. Invest., Vol. 20, (1990), pp. 516–524. http://dx.doi.org/10.1111/j.1365-2362.1990.tb01920.x[Crossref]
• [15] T. Suzuki, H. Kondo and S. Kashiwazaki: “Antibodies to vimentin and cytokeratin in patients with connective tissue diseases”, Jpn. J. Clin. Immunol., Vol. 12, (1989), pp. 184–191.
• [16] E.R. Vossenaar, N. Despres, E. Lapointe and A. Van der Heijden: “Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin”, Arthritis Res. Ther., Vol. 6, (2004), pp. 142–150. http://dx.doi.org/10.1186/ar1149[Crossref]
• [17] J.L. Senecal, J.M. Oliver and N. Rothfield: “Anticytoskeletal autoantibodies in the connective tissue diseases”, Arthritis Rheum., Vol. 28, (1985), pp. 889–898. [Crossref]
• [18] J.L. Senecal, N.F. Rothfield and J.M. Oliver: “Immunoglobulin M autoantibody to vimentin intermediate filaments”, J. Clin. Invest., Vol. 69, (1982), pp. 716–721. http://dx.doi.org/10.1172/JCI110500[Crossref]
• [19] A.R. Bradwell, R.P. Stokes and G.D. Johnson: Atlas of Hep-2 patterns, 1st ed., The Binding Site LTD, Birmingham, 1995.
• [20] B.T. Helfland, L. Chang and R.D. Goldman: “Intermediate filaments are dynamic and motile elements of cellular architecture”, J. Cell. Sci., Vol. 117, (2004), pp. 133–141 http://dx.doi.org/10.1242/jcs.00936[Crossref]
• [21] N. Wang and D. Stamenovic: “Mechanics of vimentin filaments”, J. Musc. Res. Cell. Mot., Vol. 23, (2003), pp. 535–540. http://dx.doi.org/10.1023/A:1023470709071[Crossref]
• [22] D. Tsuruta and J.C.R. Jones: “The vimentin cytoskeleton regulates focal contact size and adhesion of endothelial cells subjected to shear stress”, J. Cell. Sci., Vol. 116, (2003), pp. 4977–4984. http://dx.doi.org/10.1242/jcs.00823[Crossref]
• [23] R.B. Nagle: “Intermediate filaments: a review of the basic biology”, Am. J. Surg. Pathol., Vol. 12, (1988), pp. 4–16.
• [24] A. Brunell, V. Labas, S. Mailloux and S. Sharma: “Proteomic study of human umbilical vein endothelial cells in culture”, Proteomics, Vol. 3, (2003), pp. 714–723. http://dx.doi.org/10.1002/pmic.200300409[Crossref]
• [25] A.D. Collins and A. Ationu: “The role of anti-endothelial antibodies in the immunopathogenesis of transplant associated coronary artery disease”, Int. J. Mol. Med., Vol. 1, (1998), pp. 439–452.
• [26] Y. Renaudineau, C. Dugue, M. Dueymes and P. Youinou: “Antiendothelial cell antibodies in systemic lupus erythematosus”, Autoimmun Rev., Vol. 1, (2002), pp. 365–372s. http://dx.doi.org/10.1016/S1568-9972(02)00063-0[Crossref]
• [27] C. Dugue, Y. Renaudineau, C. Jamin and P. Youinou: “Diagnostic and pathogenic implications of the heterogeneity of antiendothelial cell antibodies”, Autoimmun Rev., Suppl 1, (2004), pp. S11-S13.

Identifiers

DOI

10.2478/s11536-006-0028-5